CDKL5 Deficiency Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

CDKL5 deficiency disorder, also known as CDD, is a rare genetic condition causing seizures, developmental delay, and severe intellectual disability, often beginning within months of birth and proving resistant to medication. This X-linked dominant disorder shares similarities with classic Rett syndrome, such as developmental issues and loss of language skills, but is distinguished by the early onset of recurrent seizures. CDD is caused by mutations affecting the CDKL5 protein, with some altering a critical amino acid for its kinase function and others producing nonfunctional variants. Currently, there are no approved treatments for CDD apart from Anti-Epileptic Drugs (AEDs) to manage seizures. · This disorder affects approximately 1 in 40,000 to 60,000 newborns and is one of the more prevalent genetic epilepsy forms. Thelansis’s “CDKL5 Deficiency Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Repo...